Previous 10 | Next 10 |
Gainers: Sonoma Pharmaceuticals (SNOA) +87%.aTyr Pharma (LIFE) +65%.NantHealth (NH) +63%.vTv Therapeutics (VTVT) +55%.Equus Total Return (EQS) +45%Hancock Jaffe Laboratories (HJLI) +34%.MDJM (MDJH) +25%.Foresight Autonomous (FRSX) +23%.Solid Biosciences (SLDB) +22%.22...
Gainers: Sonoma Pharmaceuticals (SNOA) +114%. NantHealth (NH) +110%. vTv Therapeutics (VTVT) +59%. aTyr Pharma (LIFE) +33%. NantKwest (NK) +22%.Losers: SELLAS Life Sciences (SLS) -33%. Immutep (IMMP) -29%. Salarius Pharmaceuticals (SLRX) -29%. Nabriva Therapeutics (NBRV) -29%. ALX O...
Investors seem to disappointed after SELLAS Life Sciences ([[SLS]] -34.8%) announces final data with up to 6 months follow-up from Phase 2 trial, VADIS evaluating its nelipepimut-S ((NPS)) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) in ductal carcinoma i...
Gainers: Immutep (IMMP) +166%.SELLAS Life Sciences (SLS) +90%.Neos Therapeutics (NEOS) +65%.Greenwich LifeSciences (GLSI) +51%.Aytu BioScience (AYTU) +34%.Veru (VERU) +34%.Silver Spike Acquisition (SSPK) +32%.8x8 (EGHT) +32%.TG Therapeutics (TGTX) +31%.Peabody Energy (BTU) +29%...
Gainers: Immutep (IMMP) +204%, Greenwich LifeSciences (GLSI) +60%, TG Therapeutics (TGTX) +37%, SELLAS Life Sciences (SLS) +28%, Anixa Biosciences (ANIX) +18%.Losers: Xenetic Biosciences (XBIO) -32%, Oncternal Therapeutics (ONCT)-26%, GeoVax L...
Immutep (IMMP) +132% after breast cancer trial shows promising survival data.Greenwich LifeSciences (GLSI) +57%.UTStarcom Holdings (UTSI) +50%.Panbela Therapeutics (PBLA) +46%.Leju Holdings (LEJU) +38%.SELLAS Life Sciences (SLS) +36%.ClearOne (CLRO) +35% to expand its footprint in M...
SELLAS Life Sciences ([[SLS]] -4.8%) announced an Exclusive License Agreement granting rights to 3DMed to develop and commercialize SELLAS’ lead late-stage clinical candidate, galinpepimut-S (‘GPS’), and its next generation heptavalent immunotherapeuatic, GPS+, across all...
- SELLAS to Potentially R eceive Up To $ 202 Million, Inclusive of $7.5 Million Upfront License Fee and $ 8 Million Near-term Milestone s, plus Tiered Royalties - - 3D Medicines to Lead Clinical Development and Commercializ...
SELLAS Life Sciences (SLS): Q3 GAAP EPS of -$0.53 misses by $0.26.Cash and equivalents totaled ~$8.2M.Press Release For further details see: SELLAS Life Sciences EPS misses by $0.26
- Received IM PD A pproval to C ommence E nrollment in France for P ivotal Phase 3 S tudy of G alinpepimut -S in A cute M yeloid L eukemia P atients - - Streng...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...